Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Biosimilares

Anti-SARS-CoV-2 RBD Reference Antibody (Tixagevimab, RUO) (VK565086)

Anti-SARS-CoV-2 RBD Reference Antibody (Tixagevimab, RUO)
Anti-SARS-CoV-2 RBD Reference Antibody (Tixagevimab, RUO)
Anti-SARS-CoV-2 RBD Reference Antibody (Tixagevimab, RUO)
Anti-SARS-CoV-2 RBD Reference Antibody (Tixagevimab, RUO)
Precio(USD):
Especificación:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoVK565086
Descripción
Tixagevimab (VK565086) is a research-grade recombinant antibody targeting Spike glycoprotein. Produced in mammalian cells with native-like glycosylation.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
  • ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especiesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
AplicacionesELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huéspedHuman
ClonalidadMonoclonal
IsotipoIgG1, kappa
Objetivo Spike glycoprotein, Spike, S glycoprotein, RBD
Nivel de endotoxinas < 10 EU/mg
Pureza >95% as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso P0DTC2
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativosAZD8895, COV2-2196, 2420564-02-7
Fondo

Spike glycoprotein (RBD) is a ~141 kDa protein. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2. When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane. When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane. Alternatively, may use NRP1/NRP2 and integrin as entry receptors.

1. Hoffmann, M. et al. (2020) Cell 181, 271-280.e8. PMID: 32142651
2. Walls, AC. et al. (2020) Cell 181, 281-292.e6. PMID: 32155444
3. Cao, W. et al. (2021) Biophysical journal 120, 1011-1019. PMID: 33607086
4. Takeda, M. (2022) Microbiology and immunology 66, 15-23. PMID: 34561887
5. Wrapp, D. et al. (2020) Science (New York, N.Y.) 367, 1260-1263. PMID: 32075877
6. Ou, X. et al. (2020) Nature communications 11, 1620. PMID: 32221306
7. Wang, J. et al. (2021) Cell discovery 7, 119. PMID: 34903715
8. Wang, X. et al. (2023) Journal of virology 97, e0161122. PMID: 36779763
9. Daly, JL. et al. (2020) Science (New York, N.Y.) 370, 861-865. PMID: 33082294
10. Cantuti-Castelvetri, L. et al. (2020) Science (New York, N.Y.) 370, 856-860. PMID: 33082293
Nota For research use only. Not suitable for clinical or therapeutic use.
Imágenes
  • Anti-SARS-CoV-2 RBD Reference Antibody (Tixagevimab, RUO)

    Bioactivity

    SEC-HPLC detection for Research Grade Tixagevimab.

  • Anti-SARS-CoV-2 RBD Reference Antibody (Tixagevimab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Tixagevimab.

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores